Learning Objectives
At the completion of this continuing medical education
activity, the participant should be able to:
Differentiate Chronic Obstructive Pulmonary Disease
and asthma on the basis of clinical and physiological
features. Identify how differences in airway inflammation impact
response to treatment in COPD and asthma. Describe clinical features that guide decision making
in management of COPD. Assess the smoking status of patients with respiratory
and/or cardiovascular symptoms. Assure that smoking cessation counseling and therapy
are readily available for patient referral. Identify symptoms that suggest depression in the
COPD patient. Recognize weight loss as a potentially severe
complication in the COPD patient.
Target Audience
Family Physicians, Physician Assistants, Registered Nurses,
Nurse Practitioners, and other Allied Health Professionals
Accreditation and Designation Statement
National Jewish Medical and Research Center is accredited by the ACCME to provide Continuing Medical Education for physicians.
National Jewish designates this educational activity
for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Faculty Chair
E. Rand Sutherland, MD, MPH
Associate Professor, Department of Medicine
Acting Associate Head, Pulmonary Division
Medical Director, Pulmonary Physiology Services
National Jewish Medical and Research Center
Associate Professor of Medicine
University of Colorado at Denver and Health Science Center
Faculty Disclosure
All faculty in a position to control the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving,
or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting
fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding
diversified mutual funds), or other financial benefit.
KEY
| # Research Grants |
~ Speaker’s Bureau |
| ^ Consultant |
> Other |
David Beuther, MD
# Merck & Co., Inc.
James Breeling, BS
Has no significant financial interest to report
Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
# AstraZeneca, Ross Products/Abbott Laboratories
Stephen K. Frankel, MD
Has no significant financial interest to report
Harold Nelson, MD
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson,Novartis, Schering Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
# Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Novartis, Sepracor, Inc., Schering Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth
Victoria C. Smith, MD
Has no significant financial interest to report
E. Rand Sutherland, MD, MPH
# GlaxoSmithKline, Boehringer Ingelheim
^ Dey, Schering-Plough, GlaxoSmithKline
Richard W. Weber, MD
^ AstraZeneca, Genentech, Novartis
~ AstraZeneca, Genentech, Novartis, GlaxoSmithKline
# Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.
Allidah Hicks, RN, MS, AE-C
Has no significant financial interest to report
Faculty Contributor
Victoria C. Smith, MD
Commercial Support
This activity is sponsored by an educational grant from Schering-Plough.
|
Adobe Acrobat Reader